Haselmeier, a provider of self-injection devices, has been granted a drug manufacturing license at its production site in Buchen, Odenwald, in accordance with §13 of the Medicines Act (Arzneimittelgesetz – AMG) or according to Art. 40 of Directive 2001/83/EC. The company can now offer pharmaceutical and biopharmaceutical companies an assembly, labeling and packaging service.

Konrad Betzler, chief quality officer of Haselmeier, said,  “I am pleased that, after extensive preparatory work and in close coordination with the responsible GMP supervisory authority, we have now received the manufacturing permit.”

Haselmeier will assemble the cartridges supplied by customers for the respective therapies with the injection pens as well as label and package the combination products. This service also includes the manufacture of batches for stability testing.